Press release - 11/12/2023 Heidelberg center for personalized medicine achieves the highest quality standards The German Cancer Society has certified the Center for Personalized Medicine (ZPM) at Heidelberg University Hospital. At the ZPM Heidelberg, patients with advanced and rare cancers and, in future, people with severe chronic inflammatory diseases will receive a molecular genetic analysis. The detailed information can open up new treatment options for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zentrum-fuer-personalisierte-medizin-heidelberg-erfuellt-hoechste-qualitaetsstandards
Microfluidic systems - 18/11/2021 Dermagnostix develops molecular diagnostic tests for skin diseases Dermagnostix GmbH has developed a rapid test to differentiate between psoriasis and eczema. This test is currently undergoing preclinical testing, with market launch planned for 2023. The start-up is already working on two other dermatological tests. Centrifugal microfluidics is the name of the technology on which the tests are based.https://www.gesundheitsindustrie-bw.de/en/article/news/dermagnostix-develops-molecular-diagnostic-tests-skin-diseases
Press release - 04/03/2024 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum valuehttps://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-pharma-announces-royalty-financing-agreement-healthcare-royalty-usd-115-million
Press release - 11/03/2021 Researchers recommend earlier start of breast cancer screening with family history of ovarian cancer Women have an increased risk of breast cancer if they have a family history of this disease. However, the risk may also be higher if first-degree family members have another type of cancer, according to a study by a team of scientists and physicians from the National Center for Tumor Diseases (NCT) Heidelberg, the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD), as well as international colleagues. https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-recommend-earlier-start-breast-cancer-screening-family-history-ovarian-cancer
Press release - 12/05/2022 New imaging method makes tiny medical robots visible in the body Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at high resolution in a living organism. This is an important step towards precise control of the robots and their clinical translation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-imaging-method-makes-tiny-medical-robots-visible-body
Innovations in the field of endoscopy - 08/06/2020 Gastroscopies with pill cameras A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.https://www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille
Press release - 18/12/2021 WHO publishes first classification of childhood tumors The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.https://www.gesundheitsindustrie-bw.de/en/article/press-release/who-publishes-first-classification-childhood-tumors
Press release - 28/08/2023 Innovative computational approach helps design proteins for cancer treatment The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment
Hummingbird Diagnostics GmbH - 22/09/2022 The great potential of blood-based microRNA analyses "The early bird catches the worm", is an apt description of what motivates Hummingbird Diagnostics GmbH from Heidelberg. The medium-sized biotechnology company analyses special biomarkers in blood, so-called microRNAs, in order to diagnose diseases at an early stage and to be able to make forecasts about the course of the disease and the success of therapy.https://www.gesundheitsindustrie-bw.de/en/article/news/great-potential-blood-based-microrna-analyses
Press release - 19/09/2023 Better distinguish chronic inflammation and cancer of the pancreas Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden
Cluster of the future - 25/11/2021 nanodiagBW: using nanopores to create completely new diagnostic possibilities Modern medicine has a wide range of molecular diagnostics at hand. In the next decade, this will increasingly be supplemented by prognostic methods. The BMBF Cluster of the Future finalist, nanodiag BW, is developing prognostic methods to identify epigenetic factors for diseases through a new type of bioanalytics – single molecule analysis in nanopores – which would make it possible to take personalised prevention approaches.https://www.gesundheitsindustrie-bw.de/en/article/news/nanodiagbw-using-nanopores-create-completely-new-diagnostic-possibilities
Article - 14/09/2022 Theranostics of prostate cancer: the combination of radionuclide diagnostics and radionuclide therapy Using a low-level radiopharmaceutical that binds to the prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography can be used to visualise even small prostate cancer metastases. Developed by Heidelberg researchers, the radiopharmaceutical is a modified radionuclide diagnostic agent that has been coupled with a powerful emitter and used as a therapeutic tracer to irradiate and destroy cancer cells from within.https://www.gesundheitsindustrie-bw.de/en/article/news/theranostics-prostate-cancer-combination-radionuclide-diagnostics-and-radionuclide-therapy
Optimised peptides against infections and cancer - 07/10/2021 New bioactive ingredients from the peptidome treasure chest Peptides are increasingly coming into scientific focus for application in diagnostics and therapy. The human body is full of these protein fragments, but only a fraction have been characterised. So there is enormous potential for discovering new biologically active substances that can help in the fight against bacteria, viruses and cancer. A collaborative research centre at Ulm University Hospital is on the trail of these promising fragments.https://www.gesundheitsindustrie-bw.de/en/article/news/new-bioactive-ingredients-peptidome-treasure-chest
Bioinspired technologies - 03/04/2020 Diagnostics with molecular scissors – is this also possible for on-site COVID-19 tests? The CRISPR-Cas gene-editing technology is one of the most important developments in molecular biology in recent years. It utilises molecular scissors with which nucleic acids can be cut and edited almost arbitrarily. Researchers in Freiburg, Germany have now successfully used the technology for diagnostic purposes. They are currently working intensively on expanding the system to enable it to detect genome sequences of the novel SARS-CoV-2 virus.https://www.gesundheitsindustrie-bw.de/en/article/news/Diagnostics-with-molecular-scissors-is-this-also-possible-for-on-site-COVID-19-tests
Expert interview - 13/05/2019 Innovation management in the life sciences – Inova DE provides insights Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…https://www.gesundheitsindustrie-bw.de/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
Article - 17/02/2021 Whole blood model enables development of early warning system for sepsis Sepsis is a life-threatening disease that can be treated all the more successfully the faster therapy is initiated. It is not just the infection itself that is so dangerous, but a dysregulated response of the immune system. Physicians at Ulm University Hospital have now developed an animal-free test system that can be used to research the disease and develop innovative diagnostic tools to quickly assess a patient's sepsis risk and optimise…https://www.gesundheitsindustrie-bw.de/en/article/news/whole-blood-model-enables-development-early-warning-system-sepsis
Press release - 09/02/2021 New rapid test to detect coronavirus antibodies developed An international research team involving the universities of Paraná and Tübingen has developed a rapid test that can reliably identify Covid-19 antibodies in the blood within minutes. As the researchers report in the journal ACS Sensors, the new process is based on a simple measuring principle making it easy to carry out without expensive instruments, and is therefore suitable for use at mobile testing centers or by laboratories.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-rapid-test-detect-coronavirus-antibodies-developed
Dossier - 01/07/2013 Electrophysiology from cardiac pacemakers to drug discovery https://www.gesundheitsindustrie-bw.de/en/article/dossier/electrophysiology-from-cardiac-pacemakers-to-drug-discovery
Press release - 18/04/2024 Collagen: Researchers at the NMI decipher how it works in medical treatment Collagen has been used in ophthalmology since the 1990s, particularly in the treatment of corneal defects. However, why and how this technique works was only known in theory. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen led by Lu Fan have found the necessary evidence and can now reliably explain how this technique works.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collagen-researchers-nmi-decipher-how-it-works-medical-treatment
Press release - 01/09/2022 Personalised antibiotic treatment strategies for tuberculosis patients Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
New method for analysing blood samples - 26/11/2020 Personalised therapy monitoring for malignant melanomas Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
Press release - 26/05/2021 Memetis continues its path to become a technology leader in Shape Memory driven miniature valving – Fluid-o-Tech S.r.l. invests an undisclosed amount to support memetis’ growth and development The Deep-Tech Start-Up memetis GmbH from Germany, which produces the world’s most compact and lightest commercially available valves driven by shape memory alloys, announces a new partnership with Fluid-o-Tech S.r.l., an Italian innovation and market leader in the field of fluid-pumps. https://www.gesundheitsindustrie-bw.de/en/article/press-release/memetis-continues-its-path-become-technology-leader-shape-memory-driven-miniature-valving-fluid-o-tech-srl-invests-undisclosed-a
Press release - 18/10/2021 More precise characterization of brain tumors improves diagnosis and therapy An international study with about 3000 patients confirms the validity of a new classification system for meningiomas. It combines tissue characteristics (histology) with molecular analyses and thus improves therapy planning.https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-characterization-brain-tumors-improves-diagnosis-and-therapy
Press release - 31/08/2022 Using nanopores to detect epigenetic changes faster Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-nanopores-detect-epigenetic-changes-faster